0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Dermatomycoses Drug Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-14A9946
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Dermatomycoses Drug Market Insights Forecast to 2028
BUY CHAPTERS

Global Dermatomycoses Drug Market Research Report 2025

Code: QYRE-Auto-14A9946
Report
January 2025
Pages:97
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Dermatomycoses Drug Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Dermatomycoses Drug Market

Dermatomycoses Drug Market

The global market for Dermatomycoses Drug was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Dermatomycoses Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dermatomycoses Drug.
The Dermatomycoses Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Dermatomycoses Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dermatomycoses Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Dermatomycoses Drug Market Report

Report Metric Details
Report Name Dermatomycoses Drug Market
CAGR 5%
Segment by Type
Segment by Application
  • Hospital
  • Clinic
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Anacor Pharmaceuticals Inc, Biolab Farmaceutica Ltda, Blueberry Therapeutics Ltd, Daewoong Pharmaceutical Co Ltd, Dermala Inc, Helix BioMedix Inc, Novan Inc, Sol-Gel Technologies Ltd, TGV-Laboratories, Viamet Pharmaceuticals Inc, Vyome Biosciences Pvt Ltd
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Dermatomycoses Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Dermatomycoses Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Dermatomycoses Drug Market report?

Ans: The main players in the Dermatomycoses Drug Market are Anacor Pharmaceuticals Inc, Biolab Farmaceutica Ltda, Blueberry Therapeutics Ltd, Daewoong Pharmaceutical Co Ltd, Dermala Inc, Helix BioMedix Inc, Novan Inc, Sol-Gel Technologies Ltd, TGV-Laboratories, Viamet Pharmaceuticals Inc, Vyome Biosciences Pvt Ltd

What are the Application segmentation covered in the Dermatomycoses Drug Market report?

Ans: The Applications covered in the Dermatomycoses Drug Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Dermatomycoses Drug Market report?

Ans: The Types covered in the Dermatomycoses Drug Market report are BB-2603, Clotrimazole, Dapaconazole, Others

Recommended Reports

Antifungal Drugs

Dermatology Treatments

Infectious Disease Therapy

1 Dermatomycoses Drug Market Overview
1.1 Product Definition
1.2 Dermatomycoses Drug by Type
1.2.1 Global Dermatomycoses Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 BB-2603
1.2.3 Clotrimazole
1.2.4 Dapaconazole
1.2.5 Others
1.3 Dermatomycoses Drug by Application
1.3.1 Global Dermatomycoses Drug Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Dermatomycoses Drug Market Size Estimates and Forecasts
1.4.1 Global Dermatomycoses Drug Revenue 2020-2031
1.4.2 Global Dermatomycoses Drug Sales 2020-2031
1.4.3 Global Dermatomycoses Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Dermatomycoses Drug Market Competition by Manufacturers
2.1 Global Dermatomycoses Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Dermatomycoses Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Dermatomycoses Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Dermatomycoses Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Dermatomycoses Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Dermatomycoses Drug, Product Type & Application
2.7 Global Key Manufacturers of Dermatomycoses Drug, Date of Enter into This Industry
2.8 Global Dermatomycoses Drug Market Competitive Situation and Trends
2.8.1 Global Dermatomycoses Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Dermatomycoses Drug Players Market Share by Revenue
2.8.3 Global Dermatomycoses Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Dermatomycoses Drug Market Scenario by Region
3.1 Global Dermatomycoses Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Dermatomycoses Drug Sales by Region: 2020-2031
3.2.1 Global Dermatomycoses Drug Sales by Region: 2020-2025
3.2.2 Global Dermatomycoses Drug Sales by Region: 2026-2031
3.3 Global Dermatomycoses Drug Revenue by Region: 2020-2031
3.3.1 Global Dermatomycoses Drug Revenue by Region: 2020-2025
3.3.2 Global Dermatomycoses Drug Revenue by Region: 2026-2031
3.4 North America Dermatomycoses Drug Market Facts & Figures by Country
3.4.1 North America Dermatomycoses Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Dermatomycoses Drug Sales by Country (2020-2031)
3.4.3 North America Dermatomycoses Drug Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Dermatomycoses Drug Market Facts & Figures by Country
3.5.1 Europe Dermatomycoses Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Dermatomycoses Drug Sales by Country (2020-2031)
3.5.3 Europe Dermatomycoses Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Dermatomycoses Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Dermatomycoses Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Dermatomycoses Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Dermatomycoses Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Dermatomycoses Drug Market Facts & Figures by Country
3.7.1 Latin America Dermatomycoses Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Dermatomycoses Drug Sales by Country (2020-2031)
3.7.3 Latin America Dermatomycoses Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Dermatomycoses Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Dermatomycoses Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Dermatomycoses Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Dermatomycoses Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Dermatomycoses Drug Sales by Type (2020-2031)
4.1.1 Global Dermatomycoses Drug Sales by Type (2020-2025)
4.1.2 Global Dermatomycoses Drug Sales by Type (2026-2031)
4.1.3 Global Dermatomycoses Drug Sales Market Share by Type (2020-2031)
4.2 Global Dermatomycoses Drug Revenue by Type (2020-2031)
4.2.1 Global Dermatomycoses Drug Revenue by Type (2020-2025)
4.2.2 Global Dermatomycoses Drug Revenue by Type (2026-2031)
4.2.3 Global Dermatomycoses Drug Revenue Market Share by Type (2020-2031)
4.3 Global Dermatomycoses Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Dermatomycoses Drug Sales by Application (2020-2031)
5.1.1 Global Dermatomycoses Drug Sales by Application (2020-2025)
5.1.2 Global Dermatomycoses Drug Sales by Application (2026-2031)
5.1.3 Global Dermatomycoses Drug Sales Market Share by Application (2020-2031)
5.2 Global Dermatomycoses Drug Revenue by Application (2020-2031)
5.2.1 Global Dermatomycoses Drug Revenue by Application (2020-2025)
5.2.2 Global Dermatomycoses Drug Revenue by Application (2026-2031)
5.2.3 Global Dermatomycoses Drug Revenue Market Share by Application (2020-2031)
5.3 Global Dermatomycoses Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Anacor Pharmaceuticals Inc
6.1.1 Anacor Pharmaceuticals Inc Company Information
6.1.2 Anacor Pharmaceuticals Inc Description and Business Overview
6.1.3 Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Anacor Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio
6.1.5 Anacor Pharmaceuticals Inc Recent Developments/Updates
6.2 Biolab Farmaceutica Ltda
6.2.1 Biolab Farmaceutica Ltda Company Information
6.2.2 Biolab Farmaceutica Ltda Description and Business Overview
6.2.3 Biolab Farmaceutica Ltda Dermatomycoses Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Biolab Farmaceutica Ltda Dermatomycoses Drug Product Portfolio
6.2.5 Biolab Farmaceutica Ltda Recent Developments/Updates
6.3 Blueberry Therapeutics Ltd
6.3.1 Blueberry Therapeutics Ltd Company Information
6.3.2 Blueberry Therapeutics Ltd Description and Business Overview
6.3.3 Blueberry Therapeutics Ltd Dermatomycoses Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Blueberry Therapeutics Ltd Dermatomycoses Drug Product Portfolio
6.3.5 Blueberry Therapeutics Ltd Recent Developments/Updates
6.4 Daewoong Pharmaceutical Co Ltd
6.4.1 Daewoong Pharmaceutical Co Ltd Company Information
6.4.2 Daewoong Pharmaceutical Co Ltd Description and Business Overview
6.4.3 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Product Portfolio
6.4.5 Daewoong Pharmaceutical Co Ltd Recent Developments/Updates
6.5 Dermala Inc
6.5.1 Dermala Inc Company Information
6.5.2 Dermala Inc Description and Business Overview
6.5.3 Dermala Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Dermala Inc Dermatomycoses Drug Product Portfolio
6.5.5 Dermala Inc Recent Developments/Updates
6.6 Helix BioMedix Inc
6.6.1 Helix BioMedix Inc Company Information
6.6.2 Helix BioMedix Inc Description and Business Overview
6.6.3 Helix BioMedix Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Helix BioMedix Inc Dermatomycoses Drug Product Portfolio
6.6.5 Helix BioMedix Inc Recent Developments/Updates
6.7 Novan Inc
6.7.1 Novan Inc Company Information
6.7.2 Novan Inc Description and Business Overview
6.7.3 Novan Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Novan Inc Dermatomycoses Drug Product Portfolio
6.7.5 Novan Inc Recent Developments/Updates
6.8 Sol-Gel Technologies Ltd
6.8.1 Sol-Gel Technologies Ltd Company Information
6.8.2 Sol-Gel Technologies Ltd Description and Business Overview
6.8.3 Sol-Gel Technologies Ltd Dermatomycoses Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Sol-Gel Technologies Ltd Dermatomycoses Drug Product Portfolio
6.8.5 Sol-Gel Technologies Ltd Recent Developments/Updates
6.9 TGV-Laboratories
6.9.1 TGV-Laboratories Company Information
6.9.2 TGV-Laboratories Description and Business Overview
6.9.3 TGV-Laboratories Dermatomycoses Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 TGV-Laboratories Dermatomycoses Drug Product Portfolio
6.9.5 TGV-Laboratories Recent Developments/Updates
6.10 Viamet Pharmaceuticals Inc
6.10.1 Viamet Pharmaceuticals Inc Company Information
6.10.2 Viamet Pharmaceuticals Inc Description and Business Overview
6.10.3 Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Viamet Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio
6.10.5 Viamet Pharmaceuticals Inc Recent Developments/Updates
6.11 Vyome Biosciences Pvt Ltd
6.11.1 Vyome Biosciences Pvt Ltd Company Information
6.11.2 Vyome Biosciences Pvt Ltd Description and Business Overview
6.11.3 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Product Portfolio
6.11.5 Vyome Biosciences Pvt Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Dermatomycoses Drug Industry Chain Analysis
7.2 Dermatomycoses Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Dermatomycoses Drug Production Mode & Process Analysis
7.4 Dermatomycoses Drug Sales and Marketing
7.4.1 Dermatomycoses Drug Sales Channels
7.4.2 Dermatomycoses Drug Distributors
7.5 Dermatomycoses Drug Customer Analysis
8 Dermatomycoses Drug Market Dynamics
8.1 Dermatomycoses Drug Industry Trends
8.2 Dermatomycoses Drug Market Drivers
8.3 Dermatomycoses Drug Market Challenges
8.4 Dermatomycoses Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Dermatomycoses Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Dermatomycoses Drug Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Dermatomycoses Drug Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Dermatomycoses Drug Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Dermatomycoses Drug Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Dermatomycoses Drug Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Dermatomycoses Drug Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Dermatomycoses Drug Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Dermatomycoses Drug, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Dermatomycoses Drug, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Dermatomycoses Drug, Product Type & Application
 Table 12. Global Key Manufacturers of Dermatomycoses Drug, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Dermatomycoses Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dermatomycoses Drug as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Dermatomycoses Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Dermatomycoses Drug Sales by Region (2020-2025) & (K Units)
 Table 18. Global Dermatomycoses Drug Sales Market Share by Region (2020-2025)
 Table 19. Global Dermatomycoses Drug Sales by Region (2026-2031) & (K Units)
 Table 20. Global Dermatomycoses Drug Sales Market Share by Region (2026-2031)
 Table 21. Global Dermatomycoses Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Dermatomycoses Drug Revenue Market Share by Region (2020-2025)
 Table 23. Global Dermatomycoses Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Dermatomycoses Drug Revenue Market Share by Region (2026-2031)
 Table 25. North America Dermatomycoses Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Dermatomycoses Drug Sales by Country (2020-2025) & (K Units)
 Table 27. North America Dermatomycoses Drug Sales by Country (2026-2031) & (K Units)
 Table 28. North America Dermatomycoses Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Dermatomycoses Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Dermatomycoses Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Dermatomycoses Drug Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Dermatomycoses Drug Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Dermatomycoses Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Dermatomycoses Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Dermatomycoses Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Dermatomycoses Drug Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Dermatomycoses Drug Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Dermatomycoses Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Dermatomycoses Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Dermatomycoses Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Dermatomycoses Drug Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Dermatomycoses Drug Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Dermatomycoses Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Dermatomycoses Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Dermatomycoses Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Dermatomycoses Drug Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Dermatomycoses Drug Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Dermatomycoses Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Dermatomycoses Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Dermatomycoses Drug Sales (K Units) by Type (2020-2025)
 Table 51. Global Dermatomycoses Drug Sales (K Units) by Type (2026-2031)
 Table 52. Global Dermatomycoses Drug Sales Market Share by Type (2020-2025)
 Table 53. Global Dermatomycoses Drug Sales Market Share by Type (2026-2031)
 Table 54. Global Dermatomycoses Drug Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Dermatomycoses Drug Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Dermatomycoses Drug Revenue Market Share by Type (2020-2025)
 Table 57. Global Dermatomycoses Drug Revenue Market Share by Type (2026-2031)
 Table 58. Global Dermatomycoses Drug Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Dermatomycoses Drug Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Dermatomycoses Drug Sales (K Units) by Application (2020-2025)
 Table 61. Global Dermatomycoses Drug Sales (K Units) by Application (2026-2031)
 Table 62. Global Dermatomycoses Drug Sales Market Share by Application (2020-2025)
 Table 63. Global Dermatomycoses Drug Sales Market Share by Application (2026-2031)
 Table 64. Global Dermatomycoses Drug Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Dermatomycoses Drug Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Dermatomycoses Drug Revenue Market Share by Application (2020-2025)
 Table 67. Global Dermatomycoses Drug Revenue Market Share by Application (2026-2031)
 Table 68. Global Dermatomycoses Drug Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Dermatomycoses Drug Price (USD/Unit) by Application (2026-2031)
 Table 70. Anacor Pharmaceuticals Inc Company Information
 Table 71. Anacor Pharmaceuticals Inc Description and Business Overview
 Table 72. Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. Anacor Pharmaceuticals Inc Dermatomycoses Drug Product
 Table 74. Anacor Pharmaceuticals Inc Recent Developments/Updates
 Table 75. Biolab Farmaceutica Ltda Company Information
 Table 76. Biolab Farmaceutica Ltda Description and Business Overview
 Table 77. Biolab Farmaceutica Ltda Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. Biolab Farmaceutica Ltda Dermatomycoses Drug Product
 Table 79. Biolab Farmaceutica Ltda Recent Developments/Updates
 Table 80. Blueberry Therapeutics Ltd Company Information
 Table 81. Blueberry Therapeutics Ltd Description and Business Overview
 Table 82. Blueberry Therapeutics Ltd Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. Blueberry Therapeutics Ltd Dermatomycoses Drug Product
 Table 84. Blueberry Therapeutics Ltd Recent Developments/Updates
 Table 85. Daewoong Pharmaceutical Co Ltd Company Information
 Table 86. Daewoong Pharmaceutical Co Ltd Description and Business Overview
 Table 87. Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Product
 Table 89. Daewoong Pharmaceutical Co Ltd Recent Developments/Updates
 Table 90. Dermala Inc Company Information
 Table 91. Dermala Inc Description and Business Overview
 Table 92. Dermala Inc Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. Dermala Inc Dermatomycoses Drug Product
 Table 94. Dermala Inc Recent Developments/Updates
 Table 95. Helix BioMedix Inc Company Information
 Table 96. Helix BioMedix Inc Description and Business Overview
 Table 97. Helix BioMedix Inc Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. Helix BioMedix Inc Dermatomycoses Drug Product
 Table 99. Helix BioMedix Inc Recent Developments/Updates
 Table 100. Novan Inc Company Information
 Table 101. Novan Inc Description and Business Overview
 Table 102. Novan Inc Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 103. Novan Inc Dermatomycoses Drug Product
 Table 104. Novan Inc Recent Developments/Updates
 Table 105. Sol-Gel Technologies Ltd Company Information
 Table 106. Sol-Gel Technologies Ltd Description and Business Overview
 Table 107. Sol-Gel Technologies Ltd Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 108. Sol-Gel Technologies Ltd Dermatomycoses Drug Product
 Table 109. Sol-Gel Technologies Ltd Recent Developments/Updates
 Table 110. TGV-Laboratories Company Information
 Table 111. TGV-Laboratories Description and Business Overview
 Table 112. TGV-Laboratories Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 113. TGV-Laboratories Dermatomycoses Drug Product
 Table 114. TGV-Laboratories Recent Developments/Updates
 Table 115. Viamet Pharmaceuticals Inc Company Information
 Table 116. Viamet Pharmaceuticals Inc Description and Business Overview
 Table 117. Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 118. Viamet Pharmaceuticals Inc Dermatomycoses Drug Product
 Table 119. Viamet Pharmaceuticals Inc Recent Developments/Updates
 Table 120. Vyome Biosciences Pvt Ltd Company Information
 Table 121. Vyome Biosciences Pvt Ltd Description and Business Overview
 Table 122. Vyome Biosciences Pvt Ltd Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 123. Vyome Biosciences Pvt Ltd Dermatomycoses Drug Product
 Table 124. Vyome Biosciences Pvt Ltd Recent Developments/Updates
 Table 125. Key Raw Materials Lists
 Table 126. Raw Materials Key Suppliers Lists
 Table 127. Dermatomycoses Drug Distributors List
 Table 128. Dermatomycoses Drug Customers List
 Table 129. Dermatomycoses Drug Market Trends
 Table 130. Dermatomycoses Drug Market Drivers
 Table 131. Dermatomycoses Drug Market Challenges
 Table 132. Dermatomycoses Drug Market Restraints
 Table 133. Research Programs/Design for This Report
 Table 134. Key Data Information from Secondary Sources
 Table 135. Key Data Information from Primary Sources
 Table 136. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Dermatomycoses Drug
 Figure 2. Global Dermatomycoses Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Dermatomycoses Drug Market Share by Type: 2024 & 2031
 Figure 4. BB-2603 Product Picture
 Figure 5. Clotrimazole Product Picture
 Figure 6. Dapaconazole Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global Dermatomycoses Drug Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Dermatomycoses Drug Market Share by Application: 2024 & 2031
 Figure 10. Hospital
 Figure 11. Clinic
 Figure 12. Others
 Figure 13. Global Dermatomycoses Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Dermatomycoses Drug Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Dermatomycoses Drug Sales (2020-2031) & (K Units)
 Figure 16. Global Dermatomycoses Drug Average Price (USD/Unit) & (2020-2031)
 Figure 17. Dermatomycoses Drug Report Years Considered
 Figure 18. Dermatomycoses Drug Sales Share by Manufacturers in 2024
 Figure 19. Global Dermatomycoses Drug Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Dermatomycoses Drug Players: Market Share by Revenue in Dermatomycoses Drug in 2024
 Figure 21. Dermatomycoses Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Dermatomycoses Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Dermatomycoses Drug Sales Market Share by Country (2020-2031)
 Figure 24. North America Dermatomycoses Drug Revenue Market Share by Country (2020-2031)
 Figure 25. U.S. Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Dermatomycoses Drug Sales Market Share by Country (2020-2031)
 Figure 28. Europe Dermatomycoses Drug Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Dermatomycoses Drug Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Dermatomycoses Drug Revenue Market Share by Region (2020-2031)
 Figure 36. China Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Taiwan Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Indonesia Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Thailand Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Malaysia Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Philippines Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Latin America Dermatomycoses Drug Sales Market Share by Country (2020-2031)
 Figure 47. Latin America Dermatomycoses Drug Revenue Market Share by Country (2020-2031)
 Figure 48. Mexico Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Brazil Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Argentina Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Middle East and Africa Dermatomycoses Drug Sales Market Share by Country (2020-2031)
 Figure 52. Middle East and Africa Dermatomycoses Drug Revenue Market Share by Country (2020-2031)
 Figure 53. Turkey Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Saudi Arabia Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. U.A.E Dermatomycoses Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Global Sales Market Share of Dermatomycoses Drug by Type (2020-2031)
 Figure 57. Global Revenue Market Share of Dermatomycoses Drug by Type (2020-2031)
 Figure 58. Global Dermatomycoses Drug Price (USD/Unit) by Type (2020-2031)
 Figure 59. Global Sales Market Share of Dermatomycoses Drug by Application (2020-2031)
 Figure 60. Global Revenue Market Share of Dermatomycoses Drug by Application (2020-2031)
 Figure 61. Global Dermatomycoses Drug Price (USD/Unit) by Application (2020-2031)
 Figure 62. Dermatomycoses Drug Value Chain
 Figure 63. Channels of Distribution (Direct Vs Distribution)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart